卫材在美国神经科学年会上报告卢非酰胺的最新数据

Japan's Eisai reported the latest data on its anti-epileptic drugs perampanel (trade name: Fycompa) and (trade name: Inovelon; US trade name: BANZEL) at the American Neuroscience Annual Meeting (AAN) held in Los Angeles, California, from April 21 to 27, 2018.

Rufinamide is a triazole derivative. The drug was launched in Europe in 2007. Based on a phase III clinical trial, the drug was finally launched in the United States in 2008. It is currently mainly used for the treatment of Lennox-Gastant syndrome in children over 1 year old, especially the treatment of tonic or atonic seizures.

In a phase III randomized double-blind placebo-controlled clinical trial involving 356 patients with refractory partial epilepsy, the rufinamide group reduced seizure frequency by 23.25%, which was significantly lower than the placebo group (9.8%); the treatment group's seizure reduction rate of ≥50% (32.5%) was significantly higher than the placebo group (14.3%). The adverse reactions caused by rufinamide are similar to those of other AEDs, but it should be noted that rufinamide can cause a shortening of the Q-T interval of the electrocardiogram. The latest phase III clinical trial shows that reducing the initial dose of rufinamide and slowly increasing the dose can effectively reduce the incidence of adverse reactions without affecting the efficacy.

在实验中卢非酰胺常见的副作用为：痛嗜睡，，头晕，恶心，疲劳等。 Finally, the editor of Medical Companion Travel would like to remind all patients who are currently using rufinamide that there have been a lot of rumors on the Internet and various platforms recently saying that increasing the dose of the drug can improve the therapeutic effect, or reducing the dose of the drug can reduce the occurrence of side effects. These are without any basis. Only by following the doctor's instructions can the effect of the drug itself be maximized.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.